Published in Radiother Oncol on November 01, 1994
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer (2001) 2.25
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int (2006) 2.07
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol (1998) 2.06
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study. Eur J Cancer (2010) 1.69
Hydrogen bonding in DNA base complexes. Biophys J (1981) 1.59
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol (2008) 1.44
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Primary Langerhans' cell histiocytosis of the central nervous system with fatal outcome. Case report. J Neurosurg (1996) 1.42
Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr (1990) 1.39
[Lymph node dissection in the surgical management of stage I endometrial carcinomas]. Gynecol Obstet Fertil (2003) 1.39
[Complications of laparoscopic lymphadenectomy in gynaecologic oncology. A series of 1102 procedures in 915 patients]. Gynecol Obstet Fertil (2005) 1.39
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol (1998) 1.37
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys (1996) 1.35
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer (1998) 1.32
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer (2001) 1.18
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med (2000) 1.13
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol (2012) 1.11
Lipases and esterases: a review of their sequences, structure and evolution. Biotechnol Annu Rev (1995) 1.07
Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys (1997) 1.06
Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol (2000) 1.06
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer (2010) 1.05
Base crystallization and base stacking in water. Eur J Biochem (1979) 1.05
Lack of involvement of nitric oxide in killing of Aspergillus fumigatus conidia by pulmonary alveolar macrophages. Infect Immun (1995) 1.05
Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J (2008) 1.04
Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer (1999) 1.04
Small intestine protection from radiation by means of a removable adapted prosthesis. Am J Surg (1999) 1.03
Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol (1995) 1.00
Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res (2000) 1.00
An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol (2013) 0.99
Magnetic resonance imaging in the treatment planning of radiation therapy in carcinoma of the cervix treated with the four-field pelvic technique. Int J Radiat Oncol Biol Phys (1997) 0.99
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer (2009) 0.98
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood (1998) 0.97
Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol (1999) 0.95
[Metastasis on previous hip arthroplasty: three cases]. Rev Chir Orthop Reparatrice Appar Mot (2005) 0.94
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
New Measurement of the π0 radiative decay width. Phys Rev Lett (2011) 0.94
A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol (2008) 0.94
Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer (1998) 0.93
Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol (2014) 0.93
Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol (2006) 0.91
Surface and electrostatics of cutinases. Methods Enzymol (1997) 0.91
Group B streptococcal bacteraemia in the elderly. J Med Microbiol (1998) 0.90
Detection of local recurrences of limb soft tissue sarcomas: is magnetic resonance imaging (MRI) relevant? Eur J Radiol (2009) 0.89
Physical characteristics of human transferrin from small angle neutron scattering. Biophys J (1980) 0.89
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol (1995) 0.89
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs (2013) 0.89
Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients. Ann Surg Oncol (2011) 0.89
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol (2011) 0.89
Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol (1998) 0.89
Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer (1995) 0.88
Angiosarcoma arising in a solitary schwannoma (neurilemoma) of the sciatic nerve. Am J Surg Pathol (1996) 0.88
Tufted angioma of the thigh. J Am Acad Dermatol (1994) 0.88
Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage? Gynecol Oncol (2011) 0.88
Recurrences of rectal cancers: results of a multimodal approach with intraoperative radiation therapy. French Group of IORT. Intraoperative Radiation Therapy. Int J Radiat Oncol Biol Phys (1996) 0.88
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol (1998) 0.88
Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol (2011) 0.88
Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res (1997) 0.87
Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Català-Occità. Int J Radiat Oncol Biol Phys (1999) 0.87
Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin. Ann Oncol (2010) 0.87
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Bull Cancer (1996) 0.86
[Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma]. Cancer Radiother (2004) 0.86
[Demography of radiation oncology residents in France in 2008: current situation and perspectives for the next three years]. Cancer Radiother (2009) 0.86
Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys (1998) 0.85
Long-term functional results of colonic J pouch versus straight coloanal anastomosis. Br J Surg (1999) 0.85
Hormonal action controlling mammary activity. J Dairy Sci (1985) 0.85
Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer (1992) 0.85
Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys (1988) 0.85
Clinical practice guidelines: diagnosis and immediate management of transient ischemic attacks in adults. Cerebrovasc Dis (2005) 0.85
A quantified approach to the analysis and prevention of urinary complications in radiotherapeutic treatment of cancer of the cervix. Int J Radiat Oncol Biol Phys (1987) 0.85
[Postoperative morbidity and mortality after microsurgical exclusion of cerebral arteriovenous malformations. Current data and analysis of recent literature]. Neurochirurgie (2001) 0.85
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol (2011) 0.84
[An individualized prognosis for truncal melanoma? A series of 77 cases]. Bull Cancer (2010) 0.84
[Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]. Cancer Radiother (2006) 0.84
[Radiosensitization induced by vemurafenib]. Cancer Radiother (2013) 0.84